IL292849A - A gastric retention system for administering active substances - Google Patents
A gastric retention system for administering active substancesInfo
- Publication number
- IL292849A IL292849A IL292849A IL29284922A IL292849A IL 292849 A IL292849 A IL 292849A IL 292849 A IL292849 A IL 292849A IL 29284922 A IL29284922 A IL 29284922A IL 292849 A IL292849 A IL 292849A
- Authority
- IL
- Israel
- Prior art keywords
- administration
- active agents
- gastric residence
- residence systems
- systems
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933348P | 2019-11-08 | 2019-11-08 | |
| US201962933210P | 2019-11-08 | 2019-11-08 | |
| US201962933313P | 2019-11-08 | 2019-11-08 | |
| US201962933211P | 2019-11-08 | 2019-11-08 | |
| US201962933226P | 2019-11-08 | 2019-11-08 | |
| US202062992075P | 2020-03-19 | 2020-03-19 | |
| US202063052905P | 2020-07-16 | 2020-07-16 | |
| PCT/US2020/059541 WO2021092491A1 (en) | 2019-11-08 | 2020-11-06 | Gastric residence systems for administration of active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292849A true IL292849A (en) | 2022-07-01 |
Family
ID=75849597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292849A IL292849A (en) | 2019-11-08 | 2022-05-08 | A gastric retention system for administering active substances |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220387311A1 (enExample) |
| EP (1) | EP4054545A4 (enExample) |
| JP (1) | JP2022553862A (enExample) |
| CN (1) | CN115003335A (enExample) |
| AU (1) | AU2020378438A1 (enExample) |
| BR (1) | BR112022008908A2 (enExample) |
| CA (1) | CA3160665A1 (enExample) |
| IL (1) | IL292849A (enExample) |
| MX (1) | MX2022005494A (enExample) |
| WO (1) | WO2021092491A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020117855A1 (en) | 2018-12-03 | 2020-06-11 | Lyndra, Inc. | Stomach simulating device |
| AU2020242062B2 (en) | 2019-03-20 | 2025-12-11 | Nortiva Bio, Inc. | Coatings for gastric residence dosage forms |
| BR112021018496A2 (pt) | 2019-03-20 | 2021-11-30 | Lyndra Therapeutics Inc | Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica |
| JP7847119B2 (ja) | 2020-07-29 | 2026-04-16 | ザ・セカント・グループ・エルエルシー | 架橋ポリ（セバシン酸グリセロール）を含む構造を含む形状誘導型制御放出および保持 |
| US20240390270A1 (en) * | 2021-01-19 | 2024-11-28 | Lyndra Therapeutics, Inc. | Gastric residence systems for administration of risperidone |
| AU2023209872A1 (en) * | 2022-01-19 | 2024-08-01 | Nortiva Bio, Inc. | Dosage forms for gastric retention |
| CN115227879B (zh) * | 2022-09-15 | 2023-01-06 | 北京天星博迈迪医疗器械有限公司 | 一种用于可降解关节球囊的组合物及其应用、一种可降解关节球囊及其制备方法 |
| US20240398701A1 (en) * | 2023-06-02 | 2024-12-05 | Lyndra Therapeutics, Inc. | Manufacturing methods for gastric residence systems |
| WO2025042349A1 (en) * | 2023-08-24 | 2025-02-27 | Junion Therapeutics (Xiamen) Co., Ltd. | A gastric residence article for oral administration |
| CN121752250A (zh) * | 2023-08-24 | 2026-03-27 | 厦门君德医药科技有限公司 | 一种口服胃滞留物 |
| WO2025148850A1 (zh) * | 2024-01-09 | 2025-07-17 | 厦门君德医药科技有限公司 | 一种胃滞留装置 |
| WO2025153071A1 (en) * | 2024-01-18 | 2025-07-24 | Junion Therapeutics (Xiamen) Co., Ltd. | Gastric residence article for oral administration |
| WO2025195482A1 (zh) * | 2024-03-22 | 2025-09-25 | 厦门君德医药科技有限公司 | 一种胃滞留装置 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| WO2007084460A2 (en) * | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| US9622966B2 (en) * | 2007-07-06 | 2017-04-18 | Basf Corporation | Gastroretentive composition on the basis of a water-soluble reaction product from a vinyl group-containing precursor |
| WO2011124953A2 (en) * | 2010-04-07 | 2011-10-13 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| AU2011285554C1 (en) * | 2010-08-06 | 2016-05-12 | Endoshape, Inc. | Radiopaque shape memory polymers for medical devices |
| NZ727659A (en) * | 2014-06-11 | 2021-12-24 | Massachusetts Inst Technology | Residence structures and related methods |
| US11576859B2 (en) * | 2015-10-23 | 2023-02-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| WO2017100367A1 (en) * | 2015-12-08 | 2017-06-15 | Lyndra, Inc. | Geometric configurations for gastric residence systems |
| CN109310639A (zh) * | 2016-05-27 | 2019-02-05 | 林德拉有限公司 | 用于胃驻留系统的材料结构 |
| JP2019532947A (ja) * | 2016-09-30 | 2019-11-14 | リンドラ，インコーポレイティド | アダマンタン系薬物の持続的送達のための胃内滞留システム |
| CA3066658A1 (en) * | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
| US11793751B2 (en) * | 2017-09-20 | 2023-10-24 | Lyndra Therapeutics, Inc. | Encapsulation of gastric residence systems |
| KR20220002905A (ko) * | 2019-03-25 | 2022-01-07 | 더글라스 파머수티클스 리미티드 | 서방형 약학 제제 |
-
2020
- 2020-11-06 MX MX2022005494A patent/MX2022005494A/es unknown
- 2020-11-06 EP EP20884024.9A patent/EP4054545A4/en active Pending
- 2020-11-06 CN CN202080092586.2A patent/CN115003335A/zh active Pending
- 2020-11-06 CA CA3160665A patent/CA3160665A1/en active Pending
- 2020-11-06 JP JP2022526215A patent/JP2022553862A/ja active Pending
- 2020-11-06 WO PCT/US2020/059541 patent/WO2021092491A1/en not_active Ceased
- 2020-11-06 BR BR112022008908A patent/BR112022008908A2/pt not_active Application Discontinuation
- 2020-11-06 US US17/774,132 patent/US20220387311A1/en active Pending
- 2020-11-06 AU AU2020378438A patent/AU2020378438A1/en active Pending
-
2022
- 2022-05-08 IL IL292849A patent/IL292849A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020378438A1 (en) | 2022-06-02 |
| WO2021092491A1 (en) | 2021-05-14 |
| US20220387311A1 (en) | 2022-12-08 |
| EP4054545A1 (en) | 2022-09-14 |
| CA3160665A1 (en) | 2021-05-14 |
| MX2022005494A (es) | 2022-08-11 |
| CN115003335A (zh) | 2022-09-02 |
| BR112022008908A2 (pt) | 2022-10-11 |
| EP4054545A4 (en) | 2024-02-14 |
| JP2022553862A (ja) | 2022-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292849A (en) | A gastric retention system for administering active substances | |
| IL291674A (en) | Connection of drug delivery systems | |
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| IL275639A (en) | Formulation for RNA administration | |
| ZA201708234B (en) | Delivery systems for controlled drug release | |
| AU2018297348A1 (en) | Compositions for parenteral administration of therapeutic agents | |
| MY193715A (en) | Nuclear receptor modulators (ror) for the treatment of inflammatory and autoimmune diseases | |
| IL280883A (en) | Systems for enteric delivery of therapeutic agents | |
| IL279127A (en) | Dispensing devices for drug administration | |
| IL264880A (en) | Preparations for oral administration of active substances | |
| IL286510A (en) | Coatings for dosage forms to stay in the stomach | |
| IL309664A (en) | Administration of anti-HPA-1A antibodies | |
| IL290421A (en) | A drug delivery system for the delivery of antiviral agents | |
| IL290039A (en) | Platelet assisted delivery of therapeutic compounds | |
| EP3654950A4 (en) | MICROPARTICLE FORMULATIONS FOR THE DELIVERY OF ACTIVE INGREDIENTS | |
| HK40080659A (en) | Gastric residence systems for administration of active agents | |
| EP3515438A4 (en) | ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING INTEGRAL INHIBITORS | |
| IL279128A (en) | Dispensing devices for drug administration | |
| IL304537A (en) | Gastric retention systems for risperidone administration | |
| HK40053710A (en) | Systems for enteric delivery of therapeutic agents | |
| HK40104184A (en) | Gastric residence systems for administration of risperidone | |
| EP3886913A4 (en) | IMPROVED TARGETED DELIVERY OF THERAPEUTICS | |
| HK40075570A (en) | Interconnection of drug administration systems | |
| HK40075722A (en) | Drug delivery system for the delivery of antiviral agents | |
| HK40004386A (en) | Gastric residence systems for sustained delivery of adamantane-class drugs |